Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0542-0
Abstract: SummaryBackground To evaluate the efficacy and safety of doxorubicin (ADM) combined with thalidomide (THA) as a first-line treatment for patients with refractory aggressive fibromatosis (AF). Patients and Methods Eligible patients were treated with ADM 30 mg/m2… read more here.
Keywords: study doxorubicin; refractory aggressive; patients refractory; phase study ... See more keywords
Pazopanib, a promising option for the treatment of aggressive fibromatosis
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000474
Abstract: Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase… read more here.
Keywords: pazopanib promising; treatment; promising option; aggressive fibromatosis ... See more keywords
Pediatric recurrent aggressive spinal fibromatosis with progressive kyphosis and neurological deficits
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Orthopaedic Surgery"
DOI: 10.1177/2309499019846618
Abstract: Aggressive fibromatosis is a benign, locally invasive fibroblastic proliferation that can cause compressive effects on adjacent structures. The primary cure of this disease rests in wide excision of the tumor. Unfortunately even when surgical margins… read more here.
Keywords: tumor; neurological deficits; excision; fibromatosis ... See more keywords